Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) SVP Paula Green sold 1,137 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the sale, the senior vice president now owns 88,837 shares in the company, valued at approximately $3,547,261.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Paula Green also recently made the following trade(s):
- On Tuesday, July 2nd, Paula Green sold 322 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $15,456.00.
- On Thursday, June 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $49.41, for a total value of $14,674.77.
- On Thursday, June 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total transaction of $47,120.94.
Twist Bioscience Price Performance
TWST traded down $1.45 during trading on Friday, hitting $43.97. The stock had a trading volume of 944,659 shares, compared to its average volume of 1,050,882. The company has a 50 day moving average price of $50.93 and a 200-day moving average price of $41.70. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -13.09 and a beta of 1.80.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Guggenheim began coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Scotiabank boosted their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $48.22.
Read Our Latest Stock Report on Twist Bioscience
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC increased its stake in Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Twist Bioscience by 2.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in Twist Bioscience during the fourth quarter worth about $2,296,000. New York State Common Retirement Fund grew its stake in Twist Bioscience by 5.0% during the fourth quarter. New York State Common Retirement Fund now owns 370,849 shares of the company’s stock worth $13,669,000 after buying an additional 17,715 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in Twist Bioscience in the 4th quarter valued at about $274,000.
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
- Five stocks we like better than Twist Bioscience
- ETF Screener: Uses and Step-by-Step Guide
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 8/5 – 8/9
- 3 Fintech Stocks With Good 2021 Prospects
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.